Law360, New York (October 20, 2008, 12:00 AM ET) -- GlaxoSmithKline PLC says that plaintiffs who brought an indirect purchasers action alleging the company stalled the approval of a generic version of Flonase don't have standing because they failed to state a cause of action under state antitrust and consumer protection laws.
In a motion filed Friday in the U.S. District Court for the Eastern District of Pennsylvania, the drugmaker asked the court to dismiss the amended class action, alleging that the plaintiffs are doing an end-run around a U.S. Supreme Court decision that would block...
Plaintiffs Lack Standing In Flonase Suit: GSK
To view the full article, take a free trial now.
